Archive | September, 2013

Op-Ed in Scientific American by MJFF CEO Todd Sherer highlights PPMI

This week, Scientific American published an Op-Ed by Todd Sherer, PhD, Chief Executive Office of The Michael J Fox Foundation for Parkinson's Research. The op-ed is a call to action for researchers to continue investigating the promising leads already discovered, and to expand the existing strategies in PD research through collaboration. Dr. Sherer highlights the recent PPMI results published in JAMA Neurology as a "critical milestone in pursuit of biomarkers that could lead to swifter diagnosis and drug development"

Continue reading...

Prodromal recruitment featured in Boston University news

The Boston University Medical Center (BUMC) news blog released an article this week focusing on the PPMI Prodromal Cohort. Dr. Sam Frank, PPMI Site PI at BUMC, explained the importance of this new cohort - "Understanding risk factors for Parkinson's disease could help to identify therapies that may prevent the onset of motor symptoms in future generations of PD". The article also directs readers to the Smell Survey on the MJFF website.

Continue reading...

MJFF CEO Todd Sherer discusses PPMI in Medscape interview

Todd Sherer, PhD, Chief Executive Office of The Michael J Fox Foundation for Parkinson's Research, was recently interviewed by Medscape about PPMI and other promising PD research. Dr. Sherer discusses the goal of PPMI, as well as the recent publication in JAMA Neurology using PPMI data that gives evidence of proteins in the CSF levels of which were lower in people with early PD compared with age- and gender-matched controls.

Continue reading...

PPMI PI Ken Marek interviewed on Medscape

Ken Marek, PPMI PI and Senior Scientist at the Institute for Neurodegenerative Disorders, was interviewed in an online video on Medscape.com. Dr. Marek discussed the goals of PPMI and the current state of biomarker research in PD in general. He also discussed the recent publication on the first results from PPMI, and the overlap among neurodegenerative diseases in terms of pathology.

Continue reading...

PPMI Genetic Cohort featured in The Wall Street Journal

Earlier this week, The Wall Street Journal published an article titled "Patients Share DNA for Cures", focusing on the various initiatives disease foundations are undertaking around genetics. The recent PPMI expansion to include a Genetic Cohort was a key feature of the article, highlighting the importance of studying biomarkers associated with mutation of LRRK2 and alpha-synuclein genes.

Continue reading...

Check out the PPMI ‘Smell & Your Brain’ infographic

The Michael J Fox Foundation for Parkinson's Research has designed and released a "Smell and Your Brain" Infographic to bolster recruitment for the PPMI hyposmia arm. MJFF posted the infographic on facebook and other social media outlets, and the infographic was picked up by hundreds of local online news outlets, including the LA Times.

Continue reading...

First study results featured in USA Today, Time, & Medscape

The first major study results from PPMI were recently highlighted in several national news outlets. USA Today, Time, and Medscape featured the study, which was published in the journal JAMA Neurology. Researchers sought to evaluate the baseline characteristics and relationship to clinical features of CSF biomarkers in de novo PD subjects and healthy controls enrolled in PPMI.

Continue reading...

PPMI Site OHSU featured in local media for Prodromal Cohort

Recruitment of hyposmic subjects in PPMI at the Oregon Health & Science University in Portland, Oregon was the focus of multiple online news articles . The Lund Report, KGW.com, Oregon Health & Science University News, KEX Portland,and The Columbian reported on PPMI efforts to identify individuals with a reduced sense of smell for enrollment in the prodromal cohort.

Continue reading...

PPMI featured in article on commonalities in PD and AD

Pharmaceutical Approvals Monthly profiled PPMI in an article last month, highlighting the similarities across neurodegenerative diseases like Parkinson's Disease and Alzheimer's Disease. PPMI PI Ken Marek was interviewed for the piece, and the article also focuses on the newly added Prodromal and Genetic Cohorts.

Continue reading...

First major PPMI results published in JAMA Neurology

The first major study results were published in the journal JAMA Neurology. Researchers sought to evaluate the baseline characteristics and relationship to clinical features of CSF biomarkers in de novo PD subjects and healthy controls enrolled in PPMI. They found that measures of CSF A?1-42, T-tau, P-tau181, and ?-synuclein have prognostic and diagnostic potential in early-stage PD. Further investigations using the entire PPMI cohort will test the predictive performance of CSF biomarkers for PD progression.

Continue reading...